References
- Ivert LU, Wahlgren C, Ivert L, et al. Eye complications during dupilumab treatment for severe atopic dermatitis. Acta Derm Venereol. 2019;99(4):375–378. doi:10.2340/00015555-3121
- Albader SS, Alharbi AA, Alenezi RF, et al. Dupilumab side effect in a patient with atopic dermatitis: a Case Report Study. Biologics. 2019;13:79–82. doi:10.2147/BTT.S195512
- Ariens LFM, Schaft J, Bakker DS, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy. 2020;75(1):116–126. doi:10.1111/all.14080
- Fukuda K, Ishida W, Kishimoto T, et al. Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis. Allergol Int. 2019;68(3):383–384. doi:10.1016/j.alit.2018.12.012
- Achten R, Bakker D, Ariens L, et al. Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021;9(3):1389–1392.e2. doi:10.1016/j.jaip.2020.09.042
- Popiela MZ, Barbara R, Turnbull AMJ, et al. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye. 2021. doi:10.1038/s41433-020-01379-9
- Barnett BP, Afshari NA. Dupilumab-associated mucin deficiency (DAMD). Transl Vis Sci Technol. 2020;9(3):29. doi:10.1167/tvst.9.3.29
- Nahum Y, Mimouni M, Livny E, et al. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol. 2019;104(6):776–779. doi:10.1136/bjophthalmol-2019-315010
- Maudinet A, Law-Koune S, Duretz C, et al. Ocular surface diseases induced by dupilumab in severe atopic dermatitis. Ophthalmol Ther. 2019;8(3):485–490. doi:10.1007/s40123-019-0191-9
- Tukler Henriksson J, Coursey TG, Corry DB, et al. IL-13 stimulates proliferation and expression of mucin and immunomodulatory genes in cultured conjunctival goblet cells. Invest Ophthalmol Vis Sci. 2015;56(8):4186–4197. doi:10.1167/iovs.14-15496
- Bakker DS, Ariens LFM, Luijk C, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019;180(5):1248–1249. doi:10.1111/bjd.17538
- Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018;154(10):1208–1211. doi:10.1001/jamadermatol.2018.2690